Literature DB >> 29080058

Pericarditis associated with cytarabine therapy for acute myelocytic leukemia: a case report.

Xia Yang1, Wei Liu1,2, Allie Lyons1,3, Zaiwei Song1, Suodi Zhai1,2, Kai Hu4.   

Abstract

BACKGROUND: The incidence of cytarabine-induced pericarditis is rare. So far, only a few cases have been reported worldwide. DESCRIPTION OF THE CASE: We are reporting a case of a 25-year-old male with acute myeloid leukemia (AML M2a) on chemotherapy who developed acute pericarditis after the administration of a cytarabine-containing regimen. The symptoms gradually improved after symptomatic treatment with steroids and other drugs.
CONCLUSIONS: This case demonstrates that, although pericarditis induced by cytarabine is rare, early recognition of this potentially life-threatening complication and appropriate management will usually result in the patient's recovery.

Entities:  

Keywords:  Acute myeloid leukemia; Cytarabine; Pericarditis

Mesh:

Substances:

Year:  2017        PMID: 29080058     DOI: 10.1007/s00228-017-2355-7

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Transient effusive-constrictive pericarditis due to chemotherapy.

Authors:  T Woods; B Vidarsson; D Mosher; J H Stein
Journal:  Clin Cardiol       Date:  1999-04       Impact factor: 2.882

2.  Pericarditis induced by high-dose cytosine arabinoside chemotherapy.

Authors:  C Hermans; N Straetmans; J L Michaux; A Ferrant
Journal:  Ann Hematol       Date:  1997 Jul-Aug       Impact factor: 3.673

3.  Pericarditis induced by high-dose cytarabine therapy.

Authors:  L Vaickus; L Letendre
Journal:  Arch Intern Med       Date:  1984-09

4.  Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Margaret R O'Donnell; Martin S Tallman; Camille N Abboud; Jessica K Altman; Frederick R Appelbaum; Daniel A Arber; Vijaya Bhatt; Dale Bixby; William Blum; Steven E Coutre; Marcos De Lima; Amir T Fathi; Melanie Fiorella; James M Foran; Steven D Gore; Aric C Hall; Patricia Kropf; Jeffrey Lancet; Lori J Maness; Guido Marcucci; Michael G Martin; Joseph O Moore; Rebecca Olin; Deniz Peker; Daniel A Pollyea; Keith Pratz; Farhad Ravandi; Paul J Shami; Richard M Stone; Stephen A Strickland; Eunice S Wang; Matthew Wieduwilt; Kristina Gregory; Ndiya Ogba
Journal:  J Natl Compr Canc Netw       Date:  2017-07       Impact factor: 11.908

5.  Successful administration of cytarabine after a previous anaphylactic reaction.

Authors:  M Blanca; M J Torres; M Girón; J L Corzo; A Martínez-Valverde
Journal:  Allergy       Date:  1997-10       Impact factor: 13.146

6.  Cytarabine-induced anaphylaxis. Demonstration of antibody and successful desensitization.

Authors:  A L Rassiga; H J Schwartz; W B Forman; E D Crum
Journal:  Arch Intern Med       Date:  1980-03

Review 7.  Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy.

Authors:  S Reykdal; R Sham; P Kouides
Journal:  Leuk Res       Date:  1995-02       Impact factor: 3.156

  7 in total
  2 in total

Review 1.  Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management.

Authors:  Chandra K Ala; Allan L Klein; Javid J Moslehi
Journal:  Curr Cardiol Rep       Date:  2019-11-25       Impact factor: 2.931

Review 2.  Cardio-Oncology in Childhood: State of the Art.

Authors:  Elena Bennati; Francesca Girolami; Gaia Spaziani; Giovanni Battista Calabri; Claudio Favre; Iris Parrini; Fabiana Lucà; Angela Tamburini; Silvia Favilli
Journal:  Curr Oncol Rep       Date:  2022-10-01       Impact factor: 5.945

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.